<DOC>
	<DOCNO>NCT01620931</DOCNO>
	<brief_summary>This randomize , observer-blinded , placebo-controlled study ass safety , tolerability , pharmacokinetics pharmacodynamics RO5469754 healthy volunteer . Subjects randomize cohort receive single ascend intravenous subcutaneous dos RO5469754 placebo . In-clinic period Day -1 Day 4 , safety follow-up 15 week dose .</brief_summary>
	<brief_title>A Single-Ascending-Dose Study RO5469754 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female volunteer , 18 64 year age , inclusive Body mass index ( BMI ) 18 32 kg/m2 Women childbearing potential partner must willing use two highly effective form contraception , one must barrier method , entire duration study ( study discharge ) five halflives last dose Male subject female partner childbearing potential must willing use condom sexual activity duration study ( study discharge ) five halflives last dose Pregnant lactate woman Positive test drug abuse ( include ethanol ) per local standard Willing comply nonsmoking policy inclinic part study ( Day 1 discharge Day 4 ) Positive hepatitis B , hepatitis C HIV infection History presence clinically significant disease condition Participation investigational drug device study within 60 day prior dose Current ( previous history ) exposure therapeutic investigational monoclonal antibody chimeric biomolecule Any confirm clinically significant previous allergic drug reaction , history anaphylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>